BAYER AG

DPHARM 2024 focused on innovations in clinical trials, featuring keynotes on ROI, DCTs, AI, and patient perspectives. Panels discussed efficiency, AI use, and ecosystem approaches. Outside-industry speakers offered unique insights. Technologists showcased patient-centric services. Sponsors highlighted innovation and collaboration. DPHARM Idol Disrupt finalists presented disruptive technologies, with Power winning for its patient-matching platform. The event aimed to improve clinical trials for faster, more efficient medicine delivery.

S.B., A.D., T.J.F., I.M.G., L.G., R.K.J., G.K., J.M.L., G.V.L., K.P.-J., H.I.S., J.T., R.R.W., M.W., Y.L.W. have disclosed various financial interests, including funding, advisory roles, patents, and equity. C.M.B., E.B., M.W.B., and K.P. declare no competing interests.

The global regenerative medicine market was valued at USD 29.42 billion in 2023 and is projected to reach USD 154.05 billion by 2033, driven by rising prevalence of disorders, aging population, and demand for precision medicines. North America leads with a 48.57% share, while Asia-Pacific is expected to grow at a 23.60% CAGR. Key segments include cell therapy, gene therapy, tissue engineering, and small molecules & biologics, with applications in cardiovascular, oncology, dermatology, and musculoskeletal areas. Challenges include high costs and operational inefficiencies, but opportunities exist in novel technologies and advancements in medical devices.

August 2024 biopharma deals highlight trends in bispecific T-cell engagers, CD-19 targeting in autoimmune diseases, and Chinese biopharma innovation. Merck's $1.3B acquisition of Curon's CD3xCD19 BiTE CN201 reflects confidence in early trial outcomes and market enthusiasm for BiTEs. JPMorgan reports a 50% reduction in upfront payments since 2020, indicating a more back-loaded deal structure.

A phase 3 trial comparing an investigational combination with standard care for advanced colorectal cancer failed to meet its primary endpoint of OS. The trial included 441 patients with PD-L1-positive, microsatellite stable metastatic colorectal cancer. The experimental combination of favezelimab and pembrolizumab showed no OS improvement compared to standard care, with a safety profile consistent with prior reports.

The global gene synthesis market, valued at USD 1.66 billion in 2023, is projected to grow at a CAGR of 22.74% to USD 10.5 billion by 2032, driven by advancements in synthetic biology, personalized medicine, and biopharmaceutical production. Key players like Thermo Fisher Scientific and GenScript are expanding services, with CRISPR and synthetic biology driving demand. Challenges include high costs, regulatory issues, and technical difficulties in long-sequence synthesis. Opportunities exist in agriculture, regenerative medicine, and emerging markets. The COVID-19 pandemic highlighted gene synthesis's role in vaccine development.

The contrast enhanced ultrasound market is projected to reach $2.54 billion by 2028 with a CAGR of 5.5%, driven by factors like rising cardiovascular diseases and advancements in technology. Key players include General Electric, Bayer, and Philips, with North America leading in market share.

A politician discusses the importance of STEM education, using the story of Professor Eddie Holmes' rapid identification of the COVID-19 genome to illustrate how STEM skills lead to critical job opportunities and societal benefits, emphasizing the intrinsic curiosity driving scientific inquiry.

Bayer submits sNDA to FDA for NUBEQA in combination with ADT for mHSPC, aiming to expand its use beyond current indications.